|
nasopharyngeal carcinoma |
56 |
|
radiotherapy |
27 |
|
survival |
23 |
|
chemotherapy |
17 |
|
epstein-barr virus |
16 |
|
whole-exome sequencing |
16 |
|
chemoradiotherapy |
14 |
|
randomized controlled trial |
14 |
|
cancer susceptibility genes |
13 |
|
early-age onset |
13 |
|
mst1r |
13 |
|
apobec-mediated signature |
12 |
|
nf-κb signaling |
12 |
|
somatic mutation landscape |
12 |
|
esophageal squamous cell carcinoma (escc) |
11 |
|
metastasis |
11 |
|
nasopharyngeal carcinoma (npc) |
11 |
|
nidogen-2 (nid2) |
11 |
|
npc |
11 |
|
promoter hypermethylation |
11 |
|
accelerated fractionation |
10 |
|
biomarker |
10 |
|
capecitabine |
10 |
|
case-control study |
10 |
|
late toxicity |
10 |
|
25-hydroxyvitamin d |
9 |
|
chromatin accessibility |
9 |
|
chromosome 6p |
9 |
|
dietary fiber |
9 |
|
ebv |
9 |
|
epidemiology |
9 |
|
fresh vegetable and fruit |
9 |
|
genetic epidemiology |
9 |
|
genetic variant |
9 |
|
host-virus interaction |
9 |
|
illumina humanmethylation450 |
9 |
|
leucocyte telomere length |
9 |
|
life-course |
9 |
|
methylome |
9 |
|
milk |
9 |
|
multiple imputation |
9 |
|
npc risk |
9 |
|
preserved food |
9 |
|
prognostic marker |
9 |
|
soybean product |
9 |
|
telomere biology |
9 |
|
tumor microenvironment |
9 |
|
ultraviolet radiation |
9 |
|
vitamin d |
9 |
|
vitamin d deficiency |
9 |
|
whole-genome bisulfite sequencing |
9 |
|
cigarette smoking |
8 |
|
dose-response relation |
8 |
|
nomogram |
8 |
|
oncology |
8 |
|
salvage treatment |
8 |
|
smoking cessation |
8 |
|
tyrosine kinase inhibitor |
8 |
|
blm |
7 |
|
ccdc170 |
7 |
|
dna dsb repair |
7 |
|
familial npc |
7 |
|
genetic susceptibility |
7 |
|
imrt |
7 |
|
intensity-modulated radiotherapy |
7 |
|
male |
7 |
|
medical sciences |
7 |
|
nhej |
7 |
|
pathway associations |
7 |
|
tert |
7 |
|
adult |
6 |
|
cxcl8 |
6 |
|
cxcr2 |
6 |
|
dna methylation |
6 |
|
dnmt1 |
6 |
|
early diagnosis |
6 |
|
female |
6 |
|
humans |
6 |
|
mif |
6 |
|
ms‐hrm |
6 |
|
sulforaphane |
6 |
|
treatment outcomes |
6 |
|
tumour spheres |
6 |
|
wif1 |
6 |
|
3' untranslated region |
5 |
|
aged |
5 |
|
animal experiment |
5 |
|
animal model |
5 |
|
animal tissue |
5 |
|
antigen expression |
5 |
|
breast neoplasms |
5 |
|
cancer outcomes |
5 |
|
cancer site-standardized relative survival |
5 |
|
efficacy |
5 |
|
global health |
5 |
|
health economics |
5 |
|
her2+ breast cancer |
5 |
|
her2-targeted therapy |
5 |
|
metastatic brain tumours |
5 |
|
middle aged |
5 |
|
second primary cancer |
5 |
|
survivorship |
5 |
|
treatment outcome |
5 |
|
cell-cell contact |
4 |
|
concurrent-adjuvant chemotherapy |
4 |
|
contact inhibition |
4 |
|
evi1 |
4 |
|
hong kong |
4 |
|
icg-001 |
4 |
|
mir-449a |
4 |
|
mir-96 |
4 |
|
nasopharyngeal cancer |
4 |
|
neoplasm recurrence, local |
4 |
|
partial confinement |
4 |
|
retrospective studies |
4 |
|
rigidity-dependent cell growth |
4 |
|
survival analysis |
4 |
|
aged, 80 and over |
3 |
|
antiviral agents - therapeutic use |
3 |
|
autologous stem cell transplantation |
3 |
|
brain metastases |
3 |
|
cell adhesion |
3 |
|
cell mechanics |
3 |
|
cisplatin |
3 |
|
cns metastases |
3 |
|
dna, viral - blood |
3 |
|
drug-resistance |
3 |
|
ductal carcinoma in situ |
3 |
|
electroosmosis |
3 |
|
electroporation |
3 |
|
epstein-barr virus dna |
3 |
|
ercc1 |
3 |
|
fih1 |
3 |
|
fluidic devices |
3 |
|
follow-up studies |
3 |
|
friction |
3 |
|
hepatitis b - drug therapy - virology |
3 |
|
hepatitis b virus - genetics |
3 |
|
her2-positive breast cancer |
3 |
|
incidence |
3 |
|
ion engines |
3 |
|
killer cells, natural |
3 |
|
lamivudine - therapeutic use |
3 |
|
lapatinib |
3 |
|
local failure |
3 |
|
lymphoma, t-cell - therapy |
3 |
|
mcm2 |
3 |
|
microrna |
3 |
|
mir-31 |
3 |
|
mutation |
3 |
|
nano-indentation |
3 |
|
nasal nk/t lymphoma |
3 |
|
nasopharyngeal neoplasms |
3 |
|
neratinib |
3 |
|
nose neoplasms - therapy |
3 |
|
sarcoma |
3 |
|
single nucleotide polymorphism |
3 |
|
stem cell transplantation - adverse effects |
3 |
|
survival outcome |
3 |
|
time factors |
3 |
|
transplantation, autologous |
3 |
|
virus activation |
3 |
|
adjuvant drug therapy |
2 |
|
adolescent |
2 |
|
antineoplastic agents - therapeutic use |
2 |
|
antineoplastic combined chemotherapy protocols - therapeutic use |
2 |
|
biologically effective dose |
2 |
|
brachytherapy |
2 |
|
breast neoplasms/prevention & control |
2 |
|
carcinoma, squamous cell |
2 |
|
cohort studies |
2 |
|
decision support techniques |
2 |
|
descriptive epidemiology |
2 |
|
dna mutational analysis |
2 |
|
dosimetric changes |
2 |
|
genetic counseling |
2 |
|
head and neck neoplasms |
2 |
|
head-and-neck cancer |
2 |
|
healthcare survey |
2 |
|
hepatitis b, chronic - complications - drug therapy |
2 |
|
hypoglossal nerve |
2 |
|
incidence rates |
2 |
|
lamivudine - administration & dosage |
2 |
|
lymphoid malignancies |
2 |
|
lymphoma - complications - drug therapy |
2 |
|
lymphoma - drug therapy - physiopathology |
2 |
|
mass screening |
2 |
|
molecular diagnostic techniques |
2 |
|
natural killer t-cells - pathology |
2 |
|
neoplasm recurrence, local - drug therapy |
2 |
|
neoplasms |
2 |
|
non-hodgkin lymphoma |
2 |
|
nose neoplasms - drug therapy - physiopathology |
2 |
|
ovarian cancer |
2 |
|
paclitaxel |
2 |
|
pancreatic neoplasms |
2 |
|
poly(adp-ribose) polymerase inhibitors |
2 |
|
practice guideline |
2 |
|
prognosis |
2 |
|
radiation dosimetry |
2 |
|
recurrence |
2 |
|
recurrence - prevention & control |
2 |
|
reverse transcriptase inhibitors - administration & dosage |
2 |
|
risk assessment |
2 |
|
risk factors |
2 |
|
salvage therapy |
2 |
|
surgery |
2 |
|
survivors |
2 |
|
therapeutics |
2 |
|
volumetric changes |
2 |
|
young adult |
2 |
|
5-ht3 receptor antagonist |
1 |
|
6 mv |
1 |
|
6mv photons |
1 |
|
adenocarcinoma (mucoid) |
1 |
|
adenoid cystic carcinoma |
1 |
|
adjuvant |
1 |
|
adoptive cell therapy |
1 |
|
advanced or metastatic breast cancer (a/mbc) |
1 |
|
age-period-cohort modeling |
1 |
|
androgen antagonists |
1 |
|
annual percentage change |
1 |
|
anterior commissure |
1 |
|
antineoplastic combined chemotherapy protocols |
1 |
|
asia-pacific |
1 |
|
bamh1-w |
1 |
|
biological markers |
1 |
|
bleomycin |
1 |
|
bone neoplasms |
1 |
|
breast cancer |
1 |
|
bzlf‐1 |
1 |
|
cancer |
1 |
|
cancer treatment protocols |
1 |
|
cancer vaccine |
1 |
|
carcinoma |
1 |
|
cauda equina syndrome |
1 |
|
central nervous system metastasis |
1 |
|
cerebrospinal fluid spread |
1 |
|
cervical carcinoma |
1 |
|
cervical nodal metastases |
1 |
|
cetuximab |
1 |
|
chemotherapy, adjuvant |
1 |
|
cholangiocarcinoma |
1 |
|
chondroblastoma |
1 |
|
chordoma |
1 |
|
clear cell |
1 |
|
clinically relevant genomic alteration |
1 |
|
combined modality therapy |
1 |
|
computer-assisted |
1 |
|
de novo metastasis |
1 |
|
dedifferentiation |
1 |
|
deoxycytidine/ analogs & derivatives |
1 |
|
dermatofibrosarcoma protuberans |
1 |
|
dialysis |
1 |
|
disease classification |
1 |
|
disease prognosis |
1 |
|
disease risk |
1 |
|
disease-free survival |
1 |
|
distant metastasis |
1 |
|
dna flow cytometry |
1 |
|
dna ploidy |
1 |
|
doxorubicin |
1 |
|
drug therapy |
1 |
|
early-stage |
1 |
|
eber-1 |
1 |
|
eber1 |
1 |
|
ebna1 |
1 |
|
education |
1 |
|
endoscopy |
1 |
|
epstein-barr virus (ebv) |
1 |
|
epstein-barr virus (ebv) dna |
1 |
|
epstein-barr virus infections |
1 |
|
epstein-barr virus-encoded rna stain |
1 |
|
epstein‐barr virus |
1 |
|
etoposide |
1 |
|
extremeties |
1 |
|
factor viii |
1 |
|
gemcitabine |
1 |
|
gemcitabine-cisplatin |
1 |
|
head and neck |
1 |
|
head and neck cancer |
1 |
|
hematogenous spread |
1 |
|
hemodialysis |
1 |
|
hepatocellular |
1 |
|
hormone therapy |
1 |
|
hormone-receptor positive (hr+) |
1 |
|
immunoglobulin‐g antibody |
1 |
|
immunophenotype |
1 |
|
immunotherapy |
1 |
|
in situ hybridization |
1 |
|
induction chemotherapy |
1 |
|
intensity-modulated |
1 |
|
interstitial brachytherapy |
1 |
|
intradural metastasis |
1 |
|
iridium |
1 |
|
iridium radioisotopes |
1 |
|
laryngealneoplasms |
1 |
|
local recurrence |
1 |
|
longitudinal profile |
1 |
|
lumbar spine |
1 |
|
lung cancer |
1 |
|
lung lymphoepithelioma- like carcinoma (lelc) |
1 |
|
lymph nodes |
1 |
|
lymphatic metastasis |
1 |
|
mass spectrometry |
1 |
|
medical |
1 |
|
metachronous metastasis |
1 |
|
monoclonal antibody |
1 |
|
mouth neoplasms |
1 |
|
mucocoele |
1 |
|
mucositis |
1 |
|
nasal lymphoma |
1 |
|
neoadjuvant therapy |
1 |
|
neoplasm metastasis |
1 |
|
neoplasm, residual |
1 |
|
neoplasms, germ cell and embryonal |
1 |
|
neuroendocrine tumors |
1 |
|
next-generation sequencing |
1 |
|
nk |
1 |
|
occipital lobe |
1 |
|
oncologists |
1 |
|
osteosarcoma |
1 |
|
ovarian neoplasms |
1 |
|
palliative medicine |
1 |
|
penis neoplasms |
1 |
|
pharyngectomy |
1 |
|
phase ii |
1 |
|
plasma ebv dna |
1 |
|
predictive assays |
1 |
|
prognostic biomarker |
1 |
|
prognostic factors |
1 |
|
prognostic markers |
1 |
|
proliferative fractions |
1 |
|
prophylaxis |
1 |
|
prostate neoplasms |
1 |
|
protein array analysis |
1 |
|
protein regulation |
1 |
|
proteomics |
1 |
|
quantitative pcr |
1 |
|
quantitative polymerase chain reaction (pcr) |
1 |
|
radiation-induced nausea and vomiting (rinv) |
1 |
|
radiations |
1 |
|
radiotherapy dosage |
1 |
|
radiotherapy planning |
1 |
|
radiotherapy planning, computer-assisted |
1 |
|
radiotherapy, conformal |
1 |
|
radiotherapy, intensity-modulated |
1 |
|
rapidarc |
1 |
|
registries |
1 |
|
regulatory network |
1 |
|
relapse |
1 |
|
response monitoring |
1 |
|
s-phase fraction |
1 |
|
salivary gland tumor |
1 |
|
second primary neoplasms |
1 |
|
serum |
1 |
|
soft-tissue neoplasms |
1 |
|
stent |
1 |
|
stents and prostheses |
1 |
|
systematic review |
1 |
|
t-cell lymphoma |
1 |
|
t1/t2n0 glottic cancer |
1 |
|
t1n0 glottic cancer |
1 |
|
tamoxifen |
1 |
|
taqman quantitative real time pcr |
1 |
|
targeted therapy |
1 |
|
taxoids |
1 |
|
tendons |
1 |
|
tomography, x-ray computed |
1 |
|
tomotherapy |
1 |
|
tongue cancer |
1 |
|
trans-oral brush biopsies |
1 |
|
treatment |
1 |
|
tumor marker |
1 |
|
tumour vascularity |
1 |
|
unknown primary |
1 |
|
veins, innominate |
1 |
|
venous restenosis |
1 |
|
yawning |
1 |
|
zebra |
1 |
